Saturday 17 October 2026 Export LNTH’s income statement to Excel — free account

Lantheus Holdings, Inc.

LNTH Healthcare Drug Manufacturers Specialty & Generic

Lantheus Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, up 0.50% from fiscal 2024. In the quarter to June 2026, revenue grew 2.68%, EPS was flat, free cash flow grew 13.6% and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years.

99.70 0.29 −0.29%

Follow LNTH

Alert me

Market cap: $6.5B
P/E: 23.7×
Fwd P/E: 25.3×
Dividend yield: —
F-score: 5/9
Altman Z: 4.25
Beneish M: −2.23
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 3.31%

Capital & Financial Ratios $m

Market Cap 6,530.00

Revenue 1,556.31

Net Income 275.31

Free Cash Flow 392.83

Net Debt (22.25)

Current Ratio 3.06

Debt/Equity 0.44

P/E ratio 23.68

Fwd P/E 25.30

P/S ratio 4.17

P/B ratio 4.95

Past 5Y EPS Growth —

This Y EPS Growth (10.95%)

Next Y EPS Growth 18.28%

Next Y revenue growth (4.39%)

Next 5Y EPS Growth 8.96%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 64.99%

10-year low 10-year high

P/S against its own 10 years 70.73%

10-year low 10-year high

P/B against its own 10 years 36.65%

10-year low 10-year high

EV/Sales against its own 10 years 69.96%

10-year low 10-year high

EV/FCF against its own 10 years 38.56%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	714	913	359	593
Receivables	284	329	374	354
Inventory	64	68	65	58
Other	24	16	102	22
	1,086	1,327	900	1,027

	2023	2024	2025	Q'26
Payables	41	35	43	48
ST’ Debt	1	1	1	1
Other	—	—	22	—
	187	241	333	336

Compound Annual Growth %

	10y	5y	3y
Sales	18.04%	35.35%	18.13%
Cash Flow	33.46%	88.49%	11.46%
Earnings	0.00%	0.00%	102.64%
Book Value	0.00%	16.21%	34.58%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	377	388	—	—	—
’25	373	378	384	407	1,542
’24	370	394	379	391	1,534
’23	301	322	320	354	1,296
’22	209	224	239	263	935
’21	93	101	102	130	425
’20	91	66	89	94	339

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	125	92	—	—	—
’25	108	87	105	90	390
’24	127	85	175	158	545
’23	109	(32)	117	112	305
’22	10	73	94	105	282
’21	10	26	4	14	54
’20	9	(2)	9	1	16

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	127	90	—	—	—
’25	99	79	95	81	354
’24	99	74	159	151	483
’23	99	(43)	200	100	357
’22	9	68	87	101	265
’21	23	23	2	9	58
’20	7	(4)	5	(3)	4

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	1.80	1.11	—	—	—
’25	1.02	1.12	0.41	0.82	3.41
’24	1.87	0.88	1.79	(0.17)	4.36
’23	(0.04)	1.33	1.88	1.47	4.65
’22	0.61	0.61	0.86	(1.74)	0.40
’21	0.13	(0.39)	(0.20)	(0.59)	(1.06)
’20	0.08	(0.16)	(0.10)	(0.05)	(0.25)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	1.76	7.95	12.59	14.57	8.67	13.30	23.51	47.46	50.20	47.25	Analyst estimates 2026–2028 Powerpack
	High	10.85	24.10	24.45	29.80	20.67	31.60	87.47	100.85	126.89	111.29
People
People	Employees	465	483	488	508	595	612	698	834	808	1,193
	Revenue/emp, $m	0.65	0.69	0.70	0.68	0.57	0.69	1.34	1.55	1.90	1.29
Income, $m
Income, $m	Revenue	302	331	343	347	339	425	935	1,296	1,534	1,542
	Gross margin, %	45.64	48.93	50.93	50.33	40.88	44.14	62.21	54.73	64.43	61.10
	EBT	28	40	50	29	(11)	(75)	27	411	431	314
	EBT margin, %	9.37	11.96	14.43	8.24	(3.38)	(17.65)	2.86	31.70	28.10	20.35
	Net income	27	123	41	32	(13)	(71)	28	327	312	234
	Depreciation	20	21	15	14	25	43	49	64	69	75
Per share, $
Per share, $	Revenue	9.42	8.89	8.98	8.91	6.27	6.30	13.65	18.99	22.17	22.84
	Earnings	0.84	3.31	1.06	0.81	(0.25)	(1.06)	0.41	4.79	4.52	3.46
	Cash flow	1.55	1.47	1.60	2.06	0.30	0.80	4.11	4.47	7.87	5.78
	Capex	0.10	(0.44)	(0.50)	(0.57)	(0.23)	0.05	(0.24)	0.75	(0.89)	(0.53)
	Free cash flow	1.65	1.03	1.10	1.50	0.07	0.85	3.87	5.22	6.98	5.25
	Book value	(3.32)	0.62	1.86	2.94	9.50	6.88	6.53	11.95	15.72	16.15
	Shares, m	32	37	38	39	54	67	68	68	69	67
Valuation, ×
Valuation, ×	P/E	10.41	6.38	14.76	25.32	0.00	0.00	123.59	13.20	19.79	19.35
	P/S	0.94	2.36	1.74	2.30	2.15	4.59	3.71	3.32	4.04	2.91
	P/B	0.00	33.61	8.43	6.98	1.42	4.20	7.76	5.28	5.69	4.12
	EV/Sales	1.69	2.94	2.19	2.59	2.56	4.76	3.86	3.21	3.81	3.05
	EV/FCF	9.66	25.34	17.86	15.44	221.58	35.17	13.62	11.66	12.10	13.28
Cash, $m
Cash, $m	Operating cash flow	50	55	61	80	16	54	282	305	545	390
	Capex	3	(16)	(19)	(22)	(12)	4	(17)	51	(62)	(36)
	Free cash flow	53	38	42	58	4	58	265	357	483	354
Balance, $m
Balance, $m	Working capital	67	101	143	107	104	145	430	898	1,086	567
	Total debt	278	268	266	194	218	175	558	562	566	569
	Net debt	227	192	153	101	139	76	142	(151)	(347)	210
	Shareholders’ equity	(107)	23	71	115	514	464	447	816	1,088	1,090
Returns, %
Returns, %	ROA	10.74	38.57	9.84	7.49	(2.11)	(8.22)	2.57	21.98	17.21	11.10
	ROIC	29.37	15.06	17.99	14.97	(0.40)	(7.03)	3.84	34.28	38.52	14.94
	ROE	(18.34)	(296.51)	85.94	34.12	(4.29)	(14.57)	6.16	51.73	32.82	21.45

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ELAN Elanco Animal Health Incorporated	$11.8B	— (loss-making)	278×	+10.23% (above 0%: growing)	+450.00% (above 0%: growing)	+35.56% (above 0%: growing)	58.33%	7.97%	Compare
RDY Dr. Reddy's Laboratories Ltd	$10.7B	32.9×	24.3×	−14.44% (below 0%: shrinking)	−70.00% (below 0%: shrinking)	−143.40% (below 0%: shrinking)	46.54%	4.81%	Compare
HIMS Hims & Hers Health, Inc.	$6.9B	— (loss-making)	— (loss-making)	+38.25% (above 0%: growing)	n/m	+5.09% (above 0%: growing)	63.83%	(12.90%)	Compare
ALKS Alkermes plc	$6.7B	102×	— (loss-making)	+26.97% (above 0%: growing)	−99.43% (below 0%: shrinking)	+1.13% (above 0%: growing)	80.22%	3.70%	Compare
LNTH Lantheus Holdings, Inc.	$6.5B	23.7×	25.3×	+2.68% (above 0%: growing)	0.00%	+13.55% (above 0%: growing)	62.30%	25.82%
KNSA Kiniksa Pharmaceuticals International, plc	$6.2B	73.4×	38.7×	+55.36% (above 0%: growing)	+37.50% (above 0%: growing)	+66.63% (above 0%: growing)	90.32%	11.16%	Compare
AMRX AMNEAL PHARMACEUTICALS, INC.	$6.2B	38.4×	51.6×	+9.89% (above 0%: growing)	+157.14% (above 0%: growing)	−351.41% (below 0%: shrinking)	42.01%	16.30%	Compare
RGC Regencell Bioscience Holdings Limited	$4.7B	— (loss-making)	—	—	—	+57.15% (above 0%: growing)	0.00%	—	Compare
INDV Indivior Pharmaceuticals Inc.	$4.0B	11.2×	11.8×	+13.58% (above 0%: growing)	+580.00% (above 0%: growing)	+58.57% (above 0%: growing)	85.42%	46.36%	Compare
Median of peers	$6.5B	38.4×	38.7×	+13.58%	+97.32%	+20.33%	61.08%	7.97%

All 86 Drug Manufacturers Specialty & Generic stocks →

Lantheus Holdings, Inc. (LNTH) key facts

Concern: Net income was $233.6 million, or $3.46 per share (basic), a net margin of 15.2%.
Strength: Lantheus Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, up 0.50% from fiscal 2024.
Lantheus Holdings, Inc. (LNTH) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, LNTH traded at $99.70, a market capitalization of $6.5 billion.
At that price the stock trades at 23.7× trailing-twelve-month earnings and 4.2× sales; its P/E is higher than 65% of its own readings over the past ten years.
Return on equity was 21.5% and debt-to-equity 0.44.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 4.25 (safe zone) for fiscal 2025.